<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="920">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821587</url>
  </required_header>
  <id_info>
    <org_study_id>20040658</org_study_id>
    <nct_id>NCT00821587</nct_id>
  </id_info>
  <brief_title>Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation</brief_title>
  <official_title>Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of cyclosporine, an anti-rejection drug,
      on the clearance of the hepatitis C virus in liver transplant subjects being treated with
      peg-interferon and ribavirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, single-center controlled study comparing two different
      immunosuppression regimens (CsA and TAC) in patients with recurrent HCV after LT undergoing
      antiviral therapy for HCV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hepatitis C Viral Level</measure>
    <time_frame>6 months after completion of interferon based therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Undetectable or &lt;100 COPIES/ML</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.</description>
    <arm_group_label>Cyclosporine</arm_group_label>
    <other_name>Gengraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females age 18 years and older

          -  HCV RNA positive by PCR after liver transplantation

          -  Elevated ALT at any time point after liver transplantation

          -  Protocol liver biopsy (standard of care) consistent with Stage greater than or equal
             to 2 of Ishak fibrosis score after liver transplantation

          -  Able to provide written informed consent

          -  Willing to practice acceptable birth control during the study period.

        Exclusion Criteria:

          -  Decompensated Cirrhosis

          -  hemoglobin &lt; 12 g/dl

          -  WBC &lt; 3,500/cubic mm

          -  Platelets &lt; 75,000/cubic mm

          -  Human immunodeficiency virus infection

          -  Pregnancy

          -  Positive HbsAg

          -  History of coronary artery disease, history of seizure disorder, poorly controlled
             autoimmune conditions, thyroid dysfunction, diabetes mellitus, major psychosis,
             intolerance to previous interferon-based therapy other than anemia or neutropenia

          -  History of suicidal ideation or suicidal attempts

          -  Creatinine &gt; 2.0 mg/dl

          -  Severe non-hepatic illnesses
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto J Firpi-Morell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 2, 2011</lastchanged_date>
  <firstreceived_date>January 9, 2009</firstreceived_date>
  <firstreceived_results_date>August 4, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Post Liver Transplant</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
